Cellectis S.a. logo

Cellectis S.a. Share Price Today

(NASDAQ: CLLS)

Cellectis S.a. share price is $1.28 & ₹111.32 as on 6 Mar 2025, 2.30 'hrs' IST

$1.28

0.02

(1.59%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Cellectis S.a. share price in Dollar and Rupees. Guide to invest in Cellectis S.a. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cellectis S.a., along with analyst recommendations, forecasts, and comprehensive financials.

Cellectis S.a. share price movements

  • Today's Low: $1.28
    Today's High: $1.31

    Day's Volatility :2.29%

  • 52 Weeks Low: $1.24
    52 Weeks High: $3.38

    52 Weeks Volatility :63.31%

Cellectis S.a. (CLLS) Returns

PeriodCellectis S.a.Sector (Health Care)Index (Russel 2000)
3 Months
-36.36%
2.1%
0.0%
6 Months
-44.49%
-4.1%
0.0%
1 Year
-50.0%
2.2%
0.0%
3 Years
-63.48%
11.8%
-11.6%

Cellectis S.a. (CLLS) Key Statistics

in dollars & INR

Previous Close
$1.26
Open
$1.31
Today's High
$1.31
Today's Low
$1.28
Market Capitalization
$136.3M
Today's Volume
$10.9K
52 Week High
$3.38
52 Week Low
$1.24
Revenue TTM
$36.0M
EBITDA
$-67.2M
Earnings Per Share (EPS)
$-1.16
Profit Margin
-234.39%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-82.2%

How to invest in Cellectis S.a. Stock (CLLS) from India?

It is very easy for Indian residents to invest directly in Cellectis S.a. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cellectis S.a. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cellectis S.a. or CLLS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cellectis S.a. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cellectis S.a. shares which would translate to 0.679 fractional shares of Cellectis S.a. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cellectis S.a., in just a few clicks!

Returns in Cellectis S.a. (CLLS) for Indian investors in Rupees

The Cellectis S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cellectis S.a. investment value today

Current value as on today

₹55,756

Returns

₹44,244

(-44.24%)

Returns from Cellectis S.a. Stock

₹49,206 (-49.21%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Cellectis S.a. (CLLS)

-59%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Cellectis S.a. Stock from India on INDmoney has decreased by -59% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cellectis S.a.

  • Long Focus Capital Management, LLC

    4.61%

  • Capital Research & Mgmt Co - Division 3

    1.85%

  • UBS Asset Mgmt Americas Inc

    1.44%

  • Millennium Management LLC

    0.53%

  • Baillie Gifford & Co Limited.

    0.29%

  • UBS Group AG

    0.23%

Analyst Recommendation on Cellectis S.a.

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Cellectis S.a. Stock (CLLS)

What analysts predicted

Upside of 353.12%

Target:

$5.80

Current:

$1.28

Insights on Cellectis S.a. Stock (Ticker Symbol: CLLS)

  • Price Movement

    In the last 7 days, CLLS stock has moved down by -10.0%
  • Increasing Revenue

    Revenue is up for the last 7 quarters, 139.0K → 16.2M (in $), with an average increase of 40.6% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -25.27M → -23.05M (in $), with an average increase of 9.6% per quarter
  • CLLS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 111.5%
  • CLLS vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 112.0%
  • Price to Sales

    ForCLLS every $1 of sales, investors are willing to pay $2.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

CLLS Cellectis S.a. Financials in INR & Dollars

FY18Y/Y Change
Revenue
$12.7M
↓ 49.46%
Net Income
$-78.7M
↓ 20.81%
Net Profit Margin
-618.12%
↓ 223.61%
FY19Y/Y Change
Revenue
$15.2M
↑ 19.32%
Net Income
$-90.7M
↑ 15.24%
Net Profit Margin
-597.01%
↑ 21.11%
FY20Y/Y Change
Revenue
$73.9M
↑ 386.83%
Net Income
$-72.6M
↓ 19.98%
Net Profit Margin
-98.14%
↑ 498.87%
FY21Y/Y Change
Revenue
$73.9M
↑ 0.0%
Net Income
$-86.3M
↑ 18.89%
Net Profit Margin
-116.68%
↓ 18.54%
FY22Y/Y Change
Revenue
$19.2M
↓ 74.08%
Net Income
$-98.7M
↑ 14.38%
Net Profit Margin
-514.78%
↓ 398.1%
FY23Y/Y Change
Revenue
$755.0K
↓ 96.06%
Net Income
$-101.1M
↑ 2.4%
Net Profit Margin
-13.4K%
↓ 12870.52%
Q2 FY23Q/Q Change
Revenue
$155.0K
↑ 11.51%
Net Income
$-17.5M
↓ 41.87%
Net Profit Margin
-11.3K%
↑ 10357.26%
Q3 FY23Q/Q Change
Revenue
$283.0K
↑ 82.58%
Net Income
$-42.9M
↑ 145.18%
Net Profit Margin
-15.1K%
↓ 3866.87%
Q4 FY23Q/Q Change
Revenue
$283.0K
↑ 0.0%
Net Income
$-42.9M
↑ 0.0%
Net Profit Margin
-15.1K%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
$4.5M
↑ 1500.0%
Net Income
$5.6M
↓ 113.17%
Net Profit Margin
124.62%
↑ 15270.2%
Q2 FY24Q/Q Change
Revenue
$8.1M
↑ 78.03%
Net Income
$-25.3M
↓ 547.81%
Net Profit Margin
-313.48%
↓ 438.1%
Q3 FY24Q/Q Change
Revenue
$16.2M
↑ 100.97%
Net Income
$-23.1M
↓ 8.76%
Net Profit Margin
-142.32%
↑ 171.16%
FY18Y/Y Change
Profit
$10.0M
↓ 55.72%
FY19Y/Y Change
Profit
$3.8M
↓ 61.99%
FY20Y/Y Change
Profit
$37.7M
↑ 891.94%
FY21Y/Y Change
Profit
$37.7M
↑ 0.0%
FY22Y/Y Change
Profit
$17.4M
↓ 53.82%
FY23Y/Y Change
Profit
$18.0K
↓ 99.9%
Q2 FY23Q/Q Change
Profit
$-26.0K
↓ 86.67%
Q3 FY23Q/Q Change
Profit
$-5.1M
↑ 19361.54%
Q4 FY23Q/Q Change
Profit
$116.0K
↓ 102.29%
Q1 FY24Q/Q Change
Profit
$-41.0K
↓ 135.34%
Q2 FY24Q/Q Change
Profit
$3.3M
↓ 8229.27%
Q3 FY24Q/Q Change
Profit
$11.5M
↑ 244.43%
FY18Y/Y Change
Operating Cash Flow
$-68.1M
↑ 30.21%
Investing Cash Flow
$35.6M
↑ 1896.8%
Financing Cash Flow
$236.5M
↑ 473.1%
FY19Y/Y Change
Operating Cash Flow
$-69.1M
↑ 1.47%
Investing Cash Flow
$-35.9M
↓ 200.7%
Financing Cash Flow
$-3.9M
↓ 101.63%
FY20Y/Y Change
Operating Cash Flow
$-80.3M
↑ 16.08%
Investing Cash Flow
$-54.3M
↑ 51.49%
Financing Cash Flow
$27.3M
↓ 807.46%
FY21Y/Y Change
Operating Cash Flow
$-104.6M
↑ 30.28%
Investing Cash Flow
$7.3M
↓ 113.39%
Financing Cash Flow
$47.5M
↑ 73.94%
FY22Y/Y Change
Operating Cash Flow
$-87.4M
↓ 16.37%
Investing Cash Flow
$-2.8M
↓ 137.93%
Financing Cash Flow
$1.1M
↓ 97.59%
Q2 FY23Q/Q Change
Operating Cash Flow
$-17.1M
↓ 39.65%
Investing Cash Flow
$-1.8M
↑ 0.0%
Financing Cash Flow
$1.7M
↓ 91.47%

Cellectis S.a. Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cellectis S.a. (CLLS) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectis S.a. logo
-19.23%
-44.49%
-50.0%
-63.48%
-89.6%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectis S.a. logo
NA
NA
0.0
-0.7
-0.82
-0.16
NA
1.29
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectis S.a. logo
Buy
$136.3M
-89.6%
NA
-234.39%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Cellectis S.a.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Organization
Cellectis S.a.
Employees
216
CEO
Dr. David j. d. Sourdive Ph.D.
Industry
Health Technology

Management People of Cellectis S.a.

NameTitle
Dr. Andre Choulika Ph.D.
Co-Founder, CEO & Director
Dr. David j. d. Sourdive Ph.D.
Deputy CEO, Executive VP of CMC & Manufacturing and Director
Mr. Arthur Stril
CFO & Chief Business Officer
Valerie Cros
Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat
Chief Technological Officer
Dr. Philippe Duchateau Ph.D.
Chief Scientific Officer
Ms. Marie-Bleuenn Terrier
General Counsel & Secretary of the Board of Directors
Pascalyne Wilson
Director of Communications
Ms. Kyung Nam-Wortman
Executive VP & Chief Human Resources Officer
Mr. Stephan Reynier M.Sc.
Chief Regulatory & Pharmaceutical Compliance Officer

Important FAQs about investing in CLLS Stock from India :

What is Cellectis S.a. share price today?

Cellectis S.a. share price today stands at $1.28, Open: $1.31 ; Previous Close: $1.26 ; High: $1.31 ; Low: $1.28 ; 52 Week High: $3.38 ; 52 Week Low: $1.24.

The stock opens at $1.31, after a previous close of $1.26. The stock reached a daily high of $1.31 and a low of $1.28, with a 52-week high of $3.38 and a 52-week low of $1.24.

Can Indians buy Cellectis S.a. shares?

Yes, Indians can invest in the Cellectis S.a. (CLLS) from India.

With INDmoney, you can buy Cellectis S.a. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cellectis S.a. at zero transaction cost.

How can I buy Cellectis S.a. shares from India?

It is very easy to buy Cellectis S.a. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cellectis S.a. (CLLS) be purchased?

Yes, you can buy fractional shares of Cellectis S.a. with INDmoney app.

What are the documents required to start investing in Cellectis S.a. stocks?

To start investing in Cellectis S.a., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cellectis S.a. Stock (CLLS)?

Today’s highest price of Cellectis S.a. (CLLS) is $1.31.

Today’s lowest price of Cellectis S.a. (CLLS) is $1.28.

What is today's market capitalisation of Cellectis S.a.?

Today's market capitalisation of Cellectis S.a. CLLS is 136.3M

What is the 52 Week High and Low Range of Cellectis S.a. Stock (CLLS)?

  • 52 Week High

    $3.38

  • 52 Week Low

    $1.24

What are the historical returns of Cellectis S.a. (CLLS)?

  • 1 Month Returns

    -19.23%

  • 3 Months Returns

    -44.49%

  • 1 Year Returns

    -50%

  • 5 Years Returns

    -89.6%

Who is the Chief Executive Officer (CEO) of Cellectis S.a. ?

Dr. David j. d. Sourdive Ph.D. is the current Chief Executive Officer (CEO) of Cellectis S.a..